17 August 2025 : Clinical Research
Evaluation of Inflammatory Biomarkers in Parotid Tumors
Aykut Ikinciogullari
ABCDEF 1*, Burak Hazir ABCDEF 1, Erdem Aggunlu ABCDEF 1, Mustafa Colak ACDEF 1, Serdar Ensari ADEF 1, Haci Huseyin Dere ADEF 1
DOI: 10.12659/MSM.947334
Med Sci Monit 2025; 31:e947334
Table 5 Inflammatory biomarker levels NLR, PLR, SII, and SIRI in specific benign tumor subtypes (pleomorphic adenoma and Warthin tumor).
| NLR (mean±SD, median) | PLR (mean±SD, median) | SII (mean±SD, median) | SIRI (mean±SD, median) | |
|---|---|---|---|---|
| Pleomorphic adenoma | 2.16±0.95, 1.91 | 122.66±38.78, 117.22 | 544.83±225.12, 501.47 | 0.95±0.59, 0.8 |
| Warthin tumor | 2.43±1.01, 2.2 | 111.30±43.35, 99.35 | 584.35±281.07, 534.07 | 1.31±0.66, 1.09 |
| value* | 0.051 | 0.02** | 0.562 | <0.001** |
| * Mann-Whitney U test; ** statistically significant. NLR – neutrophil to lymphocyte ratio; PLR – platelet-to-lymphocyte ratio; SII – systemic immune inflammation index; SIRI – systemic inflammation response index. | ||||